Skip to the beginning of the images gallery

MK-0429 , CAS No.M611907, Antagonist of integrin; alpha V subunit

Moligand™

PubChem CID: 9853559

Item Number

M611907

Grouped product items
SKU	Size	Availability	Price	Qty
M611907-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,300.90
M611907-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,000.90

View related series

integrin，alpha V subunit Antagonist

Basic Description

Synonyms	MK-0429\|227963-15-7\|MK-429\|CHEMBL145085\|1JL033A2D0\|(3S)-3-(6-Methoxy-3-pyridyl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid\|J1.969.455K\|(S)-3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8
Specifications & Purity	Moligand™
Grade	Moligand™
Action Type	ANTAGONIST
Mechanism of action	Antagonist of integrin; alpha V subunit

Associated Targets

ITGA2B Tclin Integrin alpha-IIb 0 Activities

Discover Target: ITGA2B

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ITGB3 Tclin Integrin beta-3 0 Activities

Discover Target: ITGB3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ITGB1 Tclin Integrin beta-1 0 Activities

Discover Target: ITGB1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ITGAV Tchem Integrin alpha-V 1 Activities

Discover Target: ITGAV

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Names and Identifiers

IUPAC Name	(3S)-3-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid
INCHI	InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1
InChi Key	HGFOOLONGOBCMP-IBGZPJMESA-N
Canonical SMILES	COc1ccc(cn1)[C@@H](N1CCN(C1=O)CCCc1ccc2c(n1)NCCC2)CC(=O)O
Isomeric SMILES	COC1=NC=C(C=C1)[C@H](CC(=O)O)N2CCN(C2=O)CCCC3=NC4=C(CCCN4)C=C3
PubChem CID	9853559

PubChem CID

9853559

ChEMBL Ligand

CHEMBL145085

BindingDB Ligand

50134778

References

1. Hutchinson JH, Halczenko W, Brashear KM, Breslin MJ, Coleman PJ, Duong LT, Fernandez-Metzler C, Gentile MA, Fisher JE, Hartman GD et al.. (2003) Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.. J Med Chem, 46 (22): (4790-8). [PMID:14561098]
2. Rosenthal MA, Davidson P, Rolland F, Campone M, Xue L, Han TH, Mehta A, Berd Y, He W, Lombardi A. (2010) Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases.. Asia Pac J Clin Oncol, 6 (1): (42-8). [PMID:20398037]
3. Pickarski M, Gleason A, Bednar B, Duong LT. (2015) Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis.. Oncol Rep, 33 (6): (2737-45). [PMID:25872534]
4. Zhou X, Zhang J, Haimbach R, Zhu W, Mayer-Ezell R, Garcia-Calvo M, Smith E, Price O, Kan Y, Zycband E et al.. (2017) An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model.. Pharmacol Res Perspect, 5 (5): (589-97). [PMID:28971604]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.